Chemotherapy or not? Sudden Death of Primary Cardiac Amyloidosis after Chemotherapy: A Case Report

Meng Luo, Yang Liu, Tian-Tian Yang, Min Mao, Ya-Yun Feng, Lu- Yang Chen, Qi Yang, Yu-Hao Hu, Yue-Ming, Chen and Jing Chang^*

Department of Internal Medicine-Cardiovascular, Chongqing Medical University, Chongqing 400016, Chinae

*Corresponding Author: Jing ChangDepartment of Internal Medicine- Cardiovascular, Chongqing Medical University, Chongqing 400016, China, E-mail: 1584105002@qq.com.

Received: February 8, 2021;Accepted: February 24, 2021; Published: March 3, 2021

Citation: Luo M, Liu Y, Yang T-T, Mao M,Feng Y-Y, et al. (2021) Chemotherapy or not? Sudden Death of Primary Cardiac Amyloidosis after Chemotherapy: A Case Report. Int J Cardiovasc Res 10:3.

Background: Cardiac amyloidosis is a relatively rare disease, which is faced with the problems of slow onset, diversification, late diagnosis, poor prognosis and limited treatment. This case focuses on whether chemotherapy is beneficial to patients in stage 3. Case Summary: This case was mainly manifested as breath shortness after activity. After cardiac color Doppler ultrasound, ECG, cardiac MRI and biopsy, it was finally diagnosed as stage of cardiac amyloidosis. Bortezomib+dexamethasone were selected and then it died suddenly after the first course of chemotherapy. Conclusion: Whether chemotherapy is needed for advanced cardiac amyloidosis requires more clinical trials and internal environmental management during the treatment.